Logo
Banner

Development of Specific Therapies Against Enterobacterales

Enterobacterales, a class of gram-negative bacteria, encompass a wide range of pathogens that pose significant challenges to public health worldwide. The emergence of multidrug-resistant strains within this group, such as Acinetobacter baumannii, has further complicated the fight against infectious diseases. Ace Infectious, a leading research and development organization, is committed to combating the threat of Enterobacterales through the development of specific therapies.

Specific Therapies against Enterobacterales

Enterobacterales display diverse mechanisms of virulence and resistance, necessitating tailored therapeutic strategies. Our specific therapies, targeting a variety of unique mechanisms employed by these bacteria, represent a promising approach to combating the virulence and resistance of these pathogens. By disrupting their ability to survive and be resistant to drugs, we can cripple the survival and proliferation of Enterobacterales, offering hope for improved treatment outcomes.

Specific Therapy Development Services Against Enterobacterales

  • Developing effective strategies for combating these infections requires a deep understanding of the mechanisms underlying bacterial pathogenesis and host response. We offer comprehensive construction services for the development of Enterobacterales infection models.
  • Enterobacterales possess a wide array of β-lactamases, classified into different groups based on their molecular structures and substrate profiles. We recognize the urgent need for innovative therapies targeting β-lactamases of Enterobacterales. Our commitment to addressing antibiotic resistance drives us to offer a range of services and expertise to support the development of effective treatments.
  • The AcrAB-TolC system is a vital component of the resistance machinery in Enterobacterales. We remain dedicated to pushing the boundaries of therapies development and contributing to the global effort to combat the AcrAB-TolC system in Enterobacterales.
  • The understanding of AI-2 quorum sensing in Enterobacterales provides a basis for developing targeted therapies. By harnessing the potential of AI-2 quorum sensing disruption, we strive to contribute to the global efforts in combating multidrug-resistant Enterobacterales infections.

We offer a comprehensive range of development services focused on combating Enterobacterales infections. With our team of experienced scientists and state-of-the-art facilities, we provide customized solutions to address the unique challenges posed by these pathogens. Our services encompass the entire development pipeline, from target identification and validation to preclinical studies.

Technology Platform We Offer

At Ace Infectious, we leverage an advanced technology platform to accelerate the development of specific therapies against Enterobacterales.

  • Cutting-edge computational modeling techniques
  • High-throughput screening techniques
  • Rational drug design techniques

Service Highlights

  • Target identification and validation. We prioritize targets based on their relevance to virulence and resistance mechanisms, ensuring a focused and effective approach.
  • Hit discovery and optimization. Using our high-throughput screening capabilities, we identify small molecule compounds or biologics that interact with the selected targets. These hits undergo iterative optimization to enhance their efficacy, selectivity, and pharmacokinetic properties.
  • Preclinical studies. Our multidisciplinary team of experts employs animal models, in vitro assays, and advanced imaging techniques to provide robust data for decision-making.

Ace Infectious is dedicated to addressing the urgent need for effective therapies against Enterobacterales, particularly multidrug-resistant strains like Acinetobacter baumannii. Our comprehensive suite of development services, coupled with our commitment to scientific excellence, positions us at the forefront of the fight against Enterobacterales.

Together, contact us to overcome the challenges posed by these superbugs.

Reference

  1. Tompkins K and van Duin D. Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. European Journal of Clinical Microbiology & Infectious Diseases, 2021, 40(10): 2053-2068.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Get in touch with our team immediately.